Mesenchymal stem cells (see our foundational MSC guide) can be sourced from different tissue types — bone marrow and adipose (fat) tissue are the two most common in current clinical practice, each with genuine trade-offs.
| Factor | Bone marrow-derived (BM-MSC) | Adipose-derived (AD-MSC) |
|---|---|---|
| Harvesting process | Aspiration, typically from the hip bone, under local anesthesia | Mini-liposuction procedure, typically from the abdomen |
| Cell yield | Generally lower yield per volume harvested | Generally higher cell yield per volume harvested |
| Harvesting discomfort | Often described as more uncomfortable during the harvesting procedure itself | Generally less uncomfortable, similar to a small liposuction procedure |
| Research history | Longer overall research and clinical history | Growing research base, increasingly common in practice |
Neither source is universally superior — the choice often comes down to specific condition being treated, cell yield needs, and patient comfort preferences. A responsible provider should explain why they recommend one source over the other for your specific case.
What affects which source is recommended
- The specific condition being treated and any condition-specific research favoring one source
- How much tissue is needed for the planned treatment
- Patient factors, including comfort with each harvesting method
A practical question to ask
Ask your provider which source they use and why, specifically for your condition — a generic "we use the best cells" answer is less informative than a specific explanation tied to your case.
What doesn't change based on source
The regulatory status discussed in our regulatory guide applies regardless of cell sourcing method — this is a technical and clinical distinction, not a regulatory one.
Ready to talk to someone?
Message us on WhatsApp for a free, no-obligation consultation.